59MO Adjuvant abemaciclib combined with endocrine therapy (ET): Efficacy results in monarchE cohort 1

Abemaciclib (oral CDK4 & 6 inhibitor) plus ET as adjuvant treatment for HR+, HER2- high risk early breast cancer (EBC), previously demonstrated robust benefit with an acceptable safety profile in the monarchE trial. Here we present efficacy data in a monarchE patient population (Cohort 1) which has a high risk of recurrence, can easily be identified in clinical practice, and recently received regulatory approval.